The 11-year long-term follow-up study from the randomized BENEFIT CIS trial

Ludwig Kappos(University Hospital of Basel), Christine Lebrun‐Frénay(Université Côte d'Azur), Jiří Fiedler, G Rice, Bernhard Hemmer(Munich Cluster for Systems Neurology), Patrick Vermersch(Inserm), Siegrid Strasser‐Fuchs, Edward Fox(Penn State Milton S. Hershey Medical Center), Michel Clanet(National Multiple Sclerosis Society), Eva Medová, Olga Zapletalová, Anthony Traboulsee(University of British Columbia), Yves Lapierre, Xavier Montalbán(Universitat de Vic - Universitat Central de Catalunya), Radomír Taláb, Martin Vališ(Charles University), Valérie Delvaux, Pierre Clavelou(Inserm), Pierre Duquette(Centre Hospitalier de l’Université de Montréal), Eva‐Maria Wicklein(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Pavel Štourač, Jean Pelletier(Hôpital de la Timone), Jason P. DeBruyne(Morehouse School of Medicine), Thomas Berger(Medical University of Vienna), Christoph Pohl, Hans‐Peter Hartung(The University of Sydney), Frederik Barkhof(National Hospital for Neurology and Neurosurgery), Dominique Dive(Centre Hospitalier Universitaire de Liège), K. Vass, Andrea Schulze(Düsseldorf University Hospital), Sven Schippling(University Hospital of Zurich), Rupert Sandbrink(Io Therapeutics (United States)), Jette Lautrup Frederiksen(University of Copenhagen), Marcelo Kremenchutzky, T. Moreau(CHU Dijon Bourgogne), Gilles Edan(Centre National de la Recherche Scientifique), Luanne M. Metz(Foothills Medical Centre), Bénédicte Dubois(University of California, San Francisco), Paul O’Connor(Augusta University), Gustavo Cruz(Düsseldorf University Hospital), Mark S. Freedman, Bruno Brochet(Centre Hospitalier Universitaire de Bordeaux), Christian Sindic(Cliniques Universitaires Saint-Luc), Mark Freedman(Ottawa Hospital), Dirk Pleimes
Neurology
August 16, 2016
Cited by 130


Related Papers